Progesterone vaginal ring - Ferring Pharmaceuticals

Drug Profile

Progesterone vaginal ring - Ferring Pharmaceuticals

Alternative Names: DR-201; Milprosa; Progesterone vaginal - Teva

Latest Information Update: 17 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Glutamate-antagonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Female infertility

Most Recent Events

  • 26 Jul 2018 Ferring Pharmaceuticals initiates the phase III SARA trial for Female infertility in USA (Vaginal) (NCT03565211)
  • 23 Jun 2018 Ferring Pharmaceuticals plans a phase III trial for Female infertility in USA (Vaginal) in July 2018 (Vaginal) (NCT03565211)
  • 28 Sep 2015 Progesterone vaginal ring licensed to Ferring Pharmaceuticals worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top